DEVELOPMENT OF A MODEL TO ASSESS THE COST-EFFECTIVENESS OF THERAPIES FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FOLLOWING A REFERENCE MODEL FRAMEWORK

被引：0
|
作者：
Aguiar-Ibanez, R. [1 ]
Palencia, R. [2 ]
Kandaswamy, P. [3 ]
Flavin, J. [4 ]
Gauthier, A. [5 ]
Davies, M. J. [6 ]
机构：
[1] Amaris Consulting Uk, London, England
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim Uk, Bracknell, Berks, England
[4] Boehringer Ingelheim Canada Ltd, Burlingon, ON, Canada
[5] Amaris, London, England
[6] Univ Leicester, Leicester, Leics, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1859
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM107
引用
收藏
页码：A562 / A562
页数：1
相关论文
共 50 条
  • [31] Vascular responsiveness in type 2 diabetes mellitus (T2DM)
    Blum, A.
    Socea, D.
    Sirchan, R.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2016, 109 (12) : 791 - 796
  • [32] The platelets characteristics in type 2 diabetes mellitus (T2DM)
    Buryachkovskaya, L.
    Uchitel, I. A.
    Sumarokov, A. B.
    Docenko, U., V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 931 - 931
  • [33] Microvascular complications in type 2 diabetes mellitus (T2DM).
    Cheung, AT
    Ramanujam, S
    Duong, PL
    Schauer, D
    Chan, LS
    Dwyre, DM
    Larkin, EC
    FASEB JOURNAL, 2002, 16 (04): : A208 - A208
  • [34] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS A DPP-4 INHIBITOR IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A440 - A440
  • [35] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA
    Teschemaker, A. R.
    Neslusan, C.
    Sabapathy, S.
    Yoong, K.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A63
  • [36] Development and Validation of a Prevalence Model for Latent Autoimmune Diabetes in Adults (LADA) Among Patients First Diagnosed with Type 2 Diabetes Mellitus (T2DM)
    Wang, Zhida
    Zhang, Jie
    Xu, Hui
    Chen, Liming
    Dove, Abigail
    MEDICAL SCIENCE MONITOR, 2021, 27
  • [37] Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
    Willis, Michael
    Nilsson, Andreas
    Kellerborg, Klas
    Ball, Philip
    Roe, Rupert
    Traina, Shana
    Beale, Rebecca
    Newell, Isabelle
    DIABETES THERAPY, 2021, 12 (01) : 313 - 328
  • [38] Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
    Michael Willis
    Andreas Nilsson
    Klas Kellerborg
    Philip Ball
    Rupert Roe
    Shana Traina
    Rebecca Beale
    Isabelle Newell
    Diabetes Therapy, 2021, 12 : 313 - 328
  • [39] Early development of diabetic nephropathy in adolescent type 2 diabetes mellitus (T2DM)
    Ettinger, LM
    DiMartino-Nardi, JR
    Flynn, JT
    PEDIATRIC RESEARCH, 2003, 53 (04) : 156A - 156A
  • [40] Early development of diabetic nephropathy in adolescent type 2 diabetes mellitus (T2DM)
    Ettinger, LM
    DiMartino-Nardi, JR
    Flynn, JT
    AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (05) : 236A - 236A
12345